What is AlonSource Group?
Alon Source Group is a prominent provider of amniotic tissue allografts designed to enhance patient recovery via advanced regenerative medicine. The company's product portfolio features amniotic membrane allografts for wound management and allograft bone for bone void filling and defect repair. Alon Source Group caters to a broad spectrum of medical fields, including sports medicine, orthopedics, spine, urology, and OB/GYN, working collaboratively with surgeons to refine existing products and pioneer novel technologies for improved patient care.
How much funding has AlonSource Group raised?
AlonSource Group has raised a total of $266K across 2 funding rounds:
Debt
$150K
Debt
$116K
Debt (2020): $150K with participation from PPP
Debt (2021): $116K led by PPP
What's next for AlonSource Group?
With its substantial late-stage funding, Alon Source Group is poised for significant expansion and further innovation in the regenerative medicine market. The strategic investment indicates confidence from stakeholders in the company's growth trajectory and its potential to capture a larger market share. Future developments are likely to focus on scaling production, expanding market reach into new medical specialties, and potentially advancing research and development for next-generation allograft technologies. This capital will be instrumental in solidifying Alon Source Group's position as a leader in therapeutic tissue solutions.
See full AlonSource Group company page
